Novogen drug acts on prostate cancer
Tuesday, 23 November, 2004
Novogen (ASX: NRT) subsidiary Marshall Edwards (LSE AIM: MSH, Nasdaq: MSHL) has reported that its lead drug phenoxodiol can slow down the progression of hormone refractory prostate cancer.
The results from a Phase Ib/IIa study of the drug in men with advanced metastatic disease were reported at the American Association of Cancer Research conference in Florida last week.
The dose response study showed that at the higher doses, the drug slowed the progression of disease and affected PSA levels over a period of 6-18 months, with no apparent toxicity, suggesting that the drug exerted an anti-tumour effect.
The company is planning a Phase IIb/IIIa multicentre international clinical trial to further test the drug in men with hormone refractory prostate cancer.
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
Neurosensing/neurostimulation implants session to be held on Monday
On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...
argenx and Monash University partner against autoimmune diseases
To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...
